The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both classes demonstrate remarkable efficacy in promoting glycemic control and facilitating substantial weight management, key

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their